Kiromic BioPharma Reports Tumor Volume Reduction in Patients
In a recent update, Kiromic BioPharma, Inc. (OTCQB: KRBP) announced encouraging efficacy results from its Deltacel-01 Phase 1 clinical trial, which investigates the effectiveness of its innovative GDT therapy in patients battling stage 4 metastatic non-small cell lung cancer (NSCLC). The trial evaluates Deltacel™ (KB-GDT-01), an off-the-shelf treatment option designed specifically for patients who have not responded to conventional therapies.
Positive Outcomes from Recent Clinical Trials
At the first patient's 12-month follow-up, a notable 33.33% reduction in tumor volume was observed compared to their size prior to treatment. This outcome signifies a partial response, marking a significant milestone for the trial, especially as the fourth patient also previously exhibited a partial response. Moreover, during the seventh patient's two-month follow-up, a 9.5% tumor size reduction was also recorded. Both patients are currently receiving treatment at the Beverly Hills Cancer Center.
Expert Insights on Trial Results
Pietro Bersani, the Chief Executive Officer of Kiromic BioPharma, expressed optimism regarding the trial results, stating, "The sustained positive results from the Deltacel-01 clinical trial are highly encouraging. Achieving a second partial response alongside the first patient’s remarkable tumor shrinkage illustrates the therapeutic potential of our gamma-delta T-cell therapy. We are expanding enrollment efforts to allow more patients to benefit from Deltacel's promising capabilities."
Treatment Update on Additional Patients
Further information from the trial includes the eighth patient, who has successfully completed the Deltacel-01 treatment protocol and is responding positively. Expected initial efficacy results for this patient will be available in a few months. Additionally, a ninth patient has commenced treatment with Deltacel at Virginia Oncology Associates.
Expanding Patient Enrollment for the Study
Kiromic is actively working toward enrolling the tenth and eleventh patients into the trial by the end of the month. This expansion is critical in generating a more comprehensive clinical dataset and understanding the efficacy of Deltacel therapy for a broader patient demographic.
More About Deltacel-01 and its Purpose
The Deltacel-01 clinical study is an open-label Phase 1 trial focusing on the safety and tolerability of gamma delta T-cell infusions in combination with low-dose radiotherapy in subjects diagnosed with advanced NSCLC. The primary goal is to assess safety, with secondary measures including evaluating response rates, progression-free survival, and overall survival among participants.
Overview of Deltacel™ and its Applications
Deltacel™ (KB-GDT-01) is an investigational cell therapy leveraging the immune system's natural ability to combat solid tumors. With a strong focus on NSCLC, which accounts for a significant portion of lung cancer cases, Deltacel™ aims to offer hope to patients who have exhausted other treatment options. Preliminary data indicates a favorable safety and efficacy profile, particularly when supplemented with localized radiation therapy.
About Kiromic BioPharma and its Commitment to Innovation
Kiromic BioPharma is a clinical-stage biotherapeutics company dedicated to developing an innovative, multi-indication allogeneic cell therapy platform harnessing the power of Gamma Delta T-cells. The company capitalizes on cutting-edge artificial intelligence technologies to discover new immuno-oncology targets, demonstrating its commitment to advancing cancer treatment methodologies. Kiromic operates out of Houston, Texas.
Frequently Asked Questions
What are the main findings of Kiromic’s latest trial?
The trial reported a 33.33% reduction in tumor volume in one patient and a 9.5% reduction in another, indicating positive responses to Deltacel therapy.
How does Deltacel™ work?
Deltacel™ utilizes gamma delta T-cells to enhance the body’s immune response against solid tumors, particularly in advanced lung cancer cases.
Where is the trial being conducted?
The trial is primarily conducted at the Beverly Hills Cancer Center but also includes additional locations such as Virginia Oncology Associates.
What are the next steps for Kiromic?
Kiromic will continue to enroll more patients in the clinical trial and will analyze the ongoing results to establish the efficacy of Deltacel therapy.
How can patients participate in the trial?
Patients interested in the trial should consult with their healthcare providers to see if they qualify and learn about enrollment opportunities.
